Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1682-1686

  Nakamura, Izumi ^a   Shibata, Masahiko ^a   Gonda, Kenji ^a   Yazawa, Takashi ^a   Shimura, Tatsuo ^a   Anazawa, Takayuki ^a   Suzuki, Satoshi ^a   Sakurai, Kenichi ^b   Koyama, Yoshihisa ^a   Ohto, Hitoshi ^a   Tomita, Ryouichi ^c   Gotoh, Mitsukazu ^a   Takenoshita, Seiichi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIPPON DENTAL UNIVERSITY   (Japan)

Author keywords

Cachexia; Colorectal cancer; Gastric cancer; Immunosuppression; Myeloid derived suppressor cells; Systemic inflammation; Vascular endothelial growth factor

Indexed keywords

ALBUMIN; CYTOKINE; INTERLEUKIN 12; PREALBUMIN; RETINOL BINDING PROTEIN; TRANSFERRIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER STAGING; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALNUTRITION; NUTRITIONAL STATUS; PERIPHERAL BLOOD MONONUCLEAR CELL; SUPPRESSOR CELL;

EID: 84875738283     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1231     Document Type: Article

References (21)

1. Goldman E: The growth of malignant disease in man and the lower animals with special reference to the vascular system. Proc R Soc Med 1: 1-13, 1907.
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
3. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
4. Ferrara N: Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55: 15-36, 2000.
5. Terheyden P, Schrama D, Pedersen LØ, et al: Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression. Scand J Immunol 58: 566-571, 2003.
6. Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174, 2009.
7. Rosenberg SO and Sinha P: Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 182: 4499-4506, 2009.
8. Rubin H: Cancer cachexia: its correlations and causes. Proc Natl Acad Sci USA 100: 5384-5389, 2003.
9. Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8: 265-269, 2005.
10. Kajdaniuk D, Marek B, Foltyn W and Kos-Kudła B: Vascular endothelial growth factor (VEGF)-part 2: in endocrinology and oncology. Endokrynol Pol 62: 456-464, 2011.
11. Sanz R, Ovejero VJ, González JJ, et al: Mortality risk scales in esophagotomy for cancer: their usefulness in preoperative patient selection. Hepatogastroenterology 53: 869-873, 2006
12. Oñate-Ocaña LF, Aiello-Crocifoglio V, Gallardo-Rincón D, et al: Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 14: 381-389, 2007.
13. Chua W, Charles KA, Baracos VE and Clarke SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104: 1288-1295, 2011.
14. Cho H, Hur HW, Kim SW, et al: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58: 15-23, 2009.
15. Nevala WK, Vachon CM, Leontovich AA, Scott CG, ThompsonMA and Markovic SN; Melanoma Study Group of the Mayo Clinic Cancer Center: Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 15: 1931-1939, 2009.
16. Coussens LM and Werb Z: Inflammation and cancer Nature 420: 860-868, 2002.
17. Shibata M, Shimura T, Gonda K, Suzuki S, Nakamura I, OhkiS, Takenoshita S: Myeloid-Derived Suppressor Cells (MDSC) is increased and correlated to immune suppression, nutritional impairment and inflammatory markers in patients with gastrointestinal cancer. 2012 ASCO Gastrointestinal Cancer Symposium (Abstract 675), 2012.
18. Ohki S, Shibata M, Gonda K, et al: Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoalbuminemia in patients with cancer. Oncol Rep 28: 453-458, 2012.
19. Gabrilovich DI, Chen DL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maduration of dendritic cells. Nat Med 2: 1096-1103, 1996.
20. Menetrier-Caux C, Montmain G, Dieu MC, et al: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-4791, 1998.
21. Gabrilovich D, Ishida T, Oyama T, et al: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92: 4150-4166, 1998.